AstraZeneca plc (AZN) Given a GBX 4,000 Price Target by Goldman Sachs Group Inc. Analysts
AstraZeneca plc (LON:AZN) has been given a GBX 4,000 ($52.21) price target by equities research analysts at Goldman Sachs Group Inc. in a note issued to investors on Tuesday. The firm currently has a a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price target would suggest a potential downside of 20.65% from the company’s previous close.
Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 4,800 ($62.66) target price on shares of AstraZeneca plc in a report on Thursday, July 21st. Jefferies Group upped their price target on AstraZeneca plc from GBX 4,600 ($60.04) to GBX 4,800 ($62.66) and gave the company a “hold” rating in a research report on Thursday, July 14th. BNP Paribas reiterated an “outperform” rating and issued a GBX 5,000 ($65.27) price target on shares of AstraZeneca plc in a research report on Wednesday, June 15th. HSBC set a GBX 4,815 ($62.85) price target on AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, August 2nd. Finally, Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 5000.50 on Tuesday. The firm’s market cap is GBX 63.26 billion. The company has a 50-day moving average price of GBX 5,007.50 and a 200-day moving average price of GBX 4,415.10. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.
The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.